21st Apr 2008 15:13
Vernalis PLC21 April 2008 21 April 2008 Vernalis Plc: Notice of Full Year 2007 Preliminary Results Winnersh, UK, 21 April 2008 -- Vernalis plc (LSE: VER) today announces that itwill be releasing its preliminary results for the twelve months ended 31December 2007 on Friday, 25 April 2008. An analyst briefing will be held at 11.00 a.m. on 25 April at the offices ofPiper Jaffray Ltd, Fifth Floor, One South Place, London EC2M 2RB. Please adviseValerie Mugridge at Brunswick if you plan to attend on +44 (0) 207 396 5325. -- ends -- Enquiries: Vernalis plc +44 (0) 118 977 3133Tony Weir, Chief Financial Officer Brunswick Group +44 (0) 20 7404 5959Jon ColesJustine McIlroyAlex Tweed Notes to Editors About Vernalis Vernalis is a speciality bio-pharmaceutical company focused on products marketedto specialist neurologists. The company has two marketed products, Frova(R) andApokyn(R), and a development pipeline focused on neurology and central nervoussystem disorders. The company has six products in clinical development andcollaborations with leading, global pharmaceutical companies including Novartis,Biogen Idec, Endo, Menarini and Chiesi: Phase Phase Phase Product Indication I II III Registration Market Marketing Rights Apokyn(R) Parkinson's X North America DiseaseFrova(R) Migraine X Menarini /Endo (Royalties)Frova(R) Menstrual X Menarini/Endo Migraine (Royalties) PreventionV1512 Parkinson's X World Wide (excl. Disease Italy)V10153 Thrombotic X World Wide DisordersV3381 Neuropathic X World Wide PainV2006 Parkinson's X Biogen Idec Disease (Royalties)V24343 Obesity X World WideAUY922 Cancer X Novartis (Royalties) For further information about Vernalis, please visit www.vernalis.com. Forward-Looking Statement This news release may contain forward-looking statements that reflect theCompany's current expectations regarding future events including the clinicaldevelopment and regulatory clearance of the Company's products, the Company'sability to find partners for the development and commercialisation of itsproducts, as well as the Company's future capital raising activities.Forward-looking statements involve risks and uncertainties. Actual events coulddiffer materially from those projected herein and depend on a number of factorsincluding the success of the Company's research strategies, the applicability ofthe discoveries made therein, the successful and timely completion of clinicalstudies, the uncertainties related to the regulatory process, the ability of theCompany to identify and agree beneficial terms with suitable partners for thecommercialisation and/or development of its products, as well as the achievementof expected synergies from such transactions, the acceptance of Frova(R) andApokyn(R) and other products by consumers and medical professionals, thesuccessful integration of completed mergers and acquisitions and achievement ofexpected synergies from such transactions, and the ability of the Company toidentify and consummate suitable strategic and business combinationtransactions. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Vernalis PLC